Fig. 6: Inhibiting pulmonary Wnt signaling activation mitigates septic ALI by downregulating CCL1.

a The protein expression of β-catenin, Lef1, TCF1/7 and b CCL1 in the lung (n = 3 for Lef1, 6 for TCF1/7 and CCL1). c A diagram of MH-S cell line treated with iCRT14 or vehicle followed by stimulation with LPS or PBS for 24 h in vitro to analyze the protein level of CCL1. d The protein level of CCL1 in MH-S cells (n = 7). e Gating strategy and frequency for Kaede red⁺ γδ T17 cells in the lung of Kaede-tg septic mice treated with CCL1- shRNA (Adv-shRNA (CCL1)) or adenovirus-negative control (Adv-NC) (n = 6). f Gating strategy and frequency of Kaede red⁺ γδ T17 cells in the lung of Kaede-tg septic mice treated with anti-CCL1 mAb or control IgG (n = 6). g Gating strategy and quantification of γδ T cells in the small intestine (n = 8). h Representative FCM plots and absolute number of Kaede red⁺ γδ T17 cells in the lung of Kaede-tg septic mice treated with vehicle or iCRT14 (n = 6). i, j Representative H&E sections of lung and histological injury scores (n = 7). 20×, Scale bar = 100 μm. 40×, Scale bar = 50 μm. k The levels of IL-17A (n = 10 for sham + vehicle, 7 for CLP + vehicle, 6 for CLP + iCRT14), IL-6 (n = 10 for sham + vehicle, 8 for CLP + vehicle and CLP + iCRT14) and total protein (n = 6) in the BALF. l The protein level of IL-17A and IL-6 in the lung (n = 6). Data are shown as mean ± SD. ^*P < 0.05, ^**P < 0.01, ^***P < 0.001, ^****P < 0.0001. ns not significant. P values were calculated using one-way ANOVA followed by Tukey’s multiple-comparison test (a, b, d, k, l), and two-sided Student’s unpaired t-test (e–h, j). Source data and exact P values are provided as a Source Data file.